These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 28262171)
1. Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series. Naono-Nagatomo K; Naono H; Abe H; Takeda R; Funahashi H; Uchimura D; Ishida Y Asian J Psychiatr; 2017 Feb; 25():36-41. PubMed ID: 28262171 [TBL] [Abstract][Full Text] [Related]
2. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Lu ML; Shen WW; Chen CH Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860 [TBL] [Abstract][Full Text] [Related]
3. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348 [TBL] [Abstract][Full Text] [Related]
4. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study. García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402 [No Abstract] [Full Text] [Related]
5. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053 [TBL] [Abstract][Full Text] [Related]
6. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534 [TBL] [Abstract][Full Text] [Related]
7. Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study. Fujioi J; Iwamoto K; Banno M; Kikuchi T; Aleksic B; Ozaki N Pharmacopsychiatry; 2017 Mar; 50(2):74-78. PubMed ID: 27656915 [No Abstract] [Full Text] [Related]
8. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426 [TBL] [Abstract][Full Text] [Related]
9. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Lee BH; Kim YK; Park SH Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367 [TBL] [Abstract][Full Text] [Related]
10. Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series. Yeager A; Shad MU Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999895 [TBL] [Abstract][Full Text] [Related]
11. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature. Kuloglu M; Ekinci O; Albayrak Y; Caykoylu A Arch Womens Ment Health; 2010 Oct; 13(5):443-7. PubMed ID: 20179976 [TBL] [Abstract][Full Text] [Related]
12. Using aripiprazole to treat new-onset hyperprolactinemia-related delusion of pregnancy. Hu LY; Lee YT; Lu T; Hung MB; Hung YY Aust N Z J Psychiatry; 2015 Oct; 49(10):946. PubMed ID: 26101399 [No Abstract] [Full Text] [Related]
13. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. Yasui-Furukori N; Furukori H; Sugawara N; Fujii A; Kaneko S J Clin Psychopharmacol; 2010 Oct; 30(5):596-9. PubMed ID: 20814333 [TBL] [Abstract][Full Text] [Related]
14. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182 [TBL] [Abstract][Full Text] [Related]
15. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Qiao Y; Yang F; Li C; Guo Q; Wen H; Zhu S; Ouyang Q; Shen W; Sheng J Psychiatry Res; 2016 Mar; 237():83-9. PubMed ID: 26921057 [TBL] [Abstract][Full Text] [Related]
16. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Nakajima M; Terao T; Iwata N; Nakamura J Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461 [TBL] [Abstract][Full Text] [Related]
17. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Chen CK; Huang YS; Ree SC; Hsiao CC Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372 [TBL] [Abstract][Full Text] [Related]
18. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. Zhao J; Song X; Ai X; Gu X; Huang G; Li X; Pang L; Ding M; Ding S; Lv L PLoS One; 2015; 10(10):e0139717. PubMed ID: 26448615 [TBL] [Abstract][Full Text] [Related]
19. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil. Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338 [TBL] [Abstract][Full Text] [Related]
20. Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy. Sugai T; Suzuki Y; Yamazaki M; Sugawara N; Yasui-Furukori N; Shimoda K; Mori T; Ozeki Y; Matsuda H; Okamoto K; Sagae T; Someya T J Clin Psychopharmacol; 2020; 40(1):14-17. PubMed ID: 31834097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]